Analysis Adds to Understanding of RV144 Vaccine Trial Results
Analyses of the RV144 HIV vaccine trial have analyzed viral variants that were able to get past the protection the vaccine offered. Those results, presented at the AIDS Vaccine 2012 conference, add to the emerging understanding that targeting certain parts of HIV's envelope protein is likely the best path to an effective vaccine.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST